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==========================

Approval of the pipeline embolization device (PED; Medtronic Inc., Minneapolis, MN, USA) in 2011 by the US Food and Drug Administration has revolutionized not only the treatment paradigm of large or giant wide-necked intracranial aneurysms in the proximal internal carotid artery (ICA) but also the treatment options available for small, distal anterior circulation, and posterior circulation aneurysms.\[[@ref1]\] Despite the widespread use of the PED, no aneurysm regrowth after its placement has been reported in the literature, although aneurysm persistence has been noted. We report the first case of complete aneurysm regrowth after on-label PED treatment of a large cavernous segment ICA aneurysm.

C[ASE]{.smallcaps} R[EPORT]{.smallcaps} {#sec1-2}
=======================================

This is a 76-year-old female with a medical history of hypertension, hyperlipidemia, and cardiac arrhythmia who was found to have a large 20 mm × 24 mm × 22 mm (width × depth × height) left cavernous carotid wide-necked aneurysm during a workup for gait instability in 2016. The patient was taking rivaroxaban for her cardiac arrhythmia and smoked one packet of cigarettes per day. Given the morphology and location of an aneurysm, the treatment of an aneurysm using the PED was recommended. Seven days before the procedure, the patient was started on aspirin (325 mg daily), and immediately before the procedure, her aspirin assay was therapeutic (462 aspirin reaction unit \[ARU\]; \<551 ARU was considered therapeutic). Her rivaroxaban was withheld 48 h before her procedure.

In March 2017, the patient underwent placement of two overlapping PED (4.5 mm × 20 mm and 5 mm × 20 mm) through the Marksman microcatheter (Medtronic Inc., Minneapolis, MN, USA) and Sofia intermediate catheter (MicroVention, Aliso Viejo, CA) for the treatment of her large left cavernous carotid aneurysm \[[Figure 1a](#F1){ref-type="fig"}\]. The first PED (4.5 mm × 20 mm) was deployed spanning from the supraclinoid ICA into the neck of the aneurysm. Then, the second PED (5 mm × 20 mm) spanning from the cavernous ICA, overlapping the distal PED, into the vertical segment of the petrous ICA was placed, covering the neck of an aneurysm. The entire flow-diverter stent construct spanned from the supraclinoid ICA to the vertical segment of the petrous ICA \[[Figure 1b](#F1){ref-type="fig"}\]. Final postprocedural control angiogram demonstrated significant contrast stasis within the aneurysm sac \[[Figure 1c](#F1){ref-type="fig"}\] while fully heparinized. The patient was continued on her aspirin and restarted on her rivaroxaban following the procedure.

![(a) Lateral angiogram demonstrating a large 20 mm × 24 mm × 22 mm (width × depth × height) left cavernous carotid wide-necked aneurysm. (b) Lateral skull X-ray demonstrating two overlapping pipeline embolization device (4.5 mm × 20 mm and 5 mm × 20 mm, Medtronic Inc., Minneapolis, MN, USA) spanning from the left supraclinoid internal carotid artery to the vertical segment of the petrous internal carotid artery. (c) Lateral angiogram demonstrating contrast stasis within the aneurysm sac following placement of the two overlapping pipeline embolization device. (d) Lateral angiogram demonstrating significant decrease aneurysm sac filling with a small residual component measuring 7 mm × 8 mm at the anterior genu of the cavernous segment of the internal carotid artery at 4 months after pipeline embolization device placement. (e) Lateral angiogram demonstrating a large regrowth of the aneurysm, measuring 25 mm × 28 mm × 18 mm, at 10 months after pipeline embolization device placement. (f) Axial computed tomography angiogram demonstrating complete coverage of the aneurysm neck by the pipeline embolization device at 10 months after treatment](JNRP-10-142-g001){#F1}

The patient returned for a follow-up angiogram at 4 months following treatment, which demonstrated remodeling of the ICA with only minimal filling of the aneurysm measuring 7 mm × 8 mm × 7 mm at the anterior genu of the cavernous segment of the ICA \[[Figure 1d](#F1){ref-type="fig"}\]. Despite counseling, the patient continued to smoke during the follow-up period. In a subsequent angiogram, at 10 months after treatment, the aneurysm had regrown with interval expansion now measuring 25 mm × 28 mm × 18 mm \[[Figure 1e](#F1){ref-type="fig"}\]. Computed tomography (CT) angiogram demonstrated complete PED coverage of the aneurysm neck \[[Figure 1f](#F1){ref-type="fig"}\]. This patient underwent placement of another PED (5 mm × 25 mm), and interval follow-up at 3 months demonstrated persistent filling of the aneurysm.

D[ISCUSSION]{.smallcaps} {#sec1-3}
========================

Flow diversion is a well-established treatment for intracranial aneurysms with higher occlusion rates and similar complication rates compared to traditional embolization techniques.\[[@ref2]\] Occlusion rates of \>85%--90% at 6--12 months after PED placement have been reported in major series in the literature with low retreatment rates.\[[@ref1][@ref3][@ref4][@ref5]\] In a recent study, comparing retreatment rates between PED alone versus PED and coil embolization, Park *et al*. reported a retreatment rate of 12% after a mean follow-up length of 9.6 months in the PED alone cohort comprising two patients with inadequate aneurysm neck coverage and six patients with persistent aneurysm filling.\[[@ref3]\] In an earlier study comprising 101 intracranial aneurysms or dissections using the PED, Fischer reported a retreatment rate of 9% for persistent or unchanged aneurysm filling on follow-up angiography.\[[@ref5]\] Other studies have reported similar rates of retreatment for incomplete aneurysm occlusion.\[[@ref4][@ref6]\] Despite a recent report of recurrence of a large middle cerebral artery aneurysm after a 6-month angiogram demonstrating complete occlusion after PED placement, no study in the literature has reported growth of an aneurysm after on-label PED use.\[[@ref7]\]

Device migrations/retraction, which may result in inadequate aneurysm neck coverage by the PED, is a well-described phenomenon.\[[@ref3][@ref8]\] However, device migration/retraction was not observed in our patient, as the CT angiogram demonstrated unchanged location and configuration of the overlapping PED construct at 10-month postprocedure. Rivaroxaban use and smoking may contribute to the aneurysm regrowth and recanalization after on-label PED use. Smoking is a known risk factor of aneurysm development and subarachnoid hemorrhage (SAH), with positive correlation between the quantity of cigarettes smoked and SAH risk. In addition, smoking may be associated with aneurysm regrowth following endovascular coil embolization.\[[@ref9]\] Similar to its effects on coiled aneurysms, smoking may preclude vessel remodeling and aneurysm sac clotting in the setting of flow diversion through its effects on vascular flow and collagen synthesis. However, data from 694 aneurysms treated using the PED have also suggested that current and former smokers have similar odds of incomplete aneurysm occlusion compared to never smokers at a mean follow-up period of 29 months.\[[@ref10]\] Given the rarity of aneurysm regrowth after flow diversion, its risk factors may be difficult to identify.

This case represents the first reported case of aneurysm regrowth with on-label PED use after initial follow-up angiography demonstrating remodeling of the ICA and near-complete occlusion at 4 months. Despite the high aneurysm occlusion rates reported with the PED, persistent aneurysm filling and aneurysm regrowth, although rare, should not be overlooked. Although no aneurysm recurrence following complete occlusion with the on-label PED placement has been reported thus far, long-term imaging follow-up for those aneurysms may be warranted. The contribution of the rivaroxaban to regrowth in this patient should be noted, but caution should be used when counseling patients about the possibility of regrowth with this technology.
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